Glucose transporter inhibitor-modified insulin for glucose-responsive insulin delivery
US11760785B2 · kind B2 · utility
0Cited by
0References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 10, 2018 |
| Grant date | Sep 19, 2023 |
| Priority date | — |
| Expiry date | Oct 23, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein is a glucose-responsive insulin delivery system based on the interaction between the glucose-modified insulin and glucose transporters (GLUTs) on erythrocytes (or red blood cells, RBCs). After being conjugated with a competitive inhibitor of a glucose transporter, insulin can efficiently bind to RBC membranes. The binding is reversible in the setting of hyperglycemia, resulting in fast release of insulin and subsequent drop of blood glucose (BG) level in vivo.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.